The effect of SGLT2 inhibition on prostate cancer Mendelian randomization and observational analysis using electronic healthcare and cohort data

被引：1

作者：

Zheng, Jie ^{[1
,2
,3
]}

Lu, Jieli ^{[1
,2
]}

Qi, Jiying ^{[1
,2
]}

Yang, Qian ^{[3
]}

Zhao, Huiling ^{[3
]}

Liu, Haoyu ^{[1
,2
]}

Chen, Zhihe ^{[1
,2
]}

Huang, Lanhui ^{[1
,2
]}

Ye, Youqiong ^{[4
,5
]}

Xu, Min ^{[1
,2
]}

Xu, Yu ^{[1
,2
]}

Wang, Tiange ^{[1
,2
]}

Li, Mian ^{[1
,2
]}

Zhao, Zhiyun ^{[1
,2
]}

Zheng, Ruizhi ^{[1
,2
]}

Wang, Shuangyuan ^{[1
,2
]}

Lin, Hong ^{[1
,2
]}

Hu, Chunyan ^{[1
,2
]}

Chui, Celine Sze Ling ^{[6
,7
,8
]}

Yeung, Shiu Lun Au ^{[7
]}

Luo, Shan ^{[3
,7
]}

Dimopoulou, Olympia ^{[3
,9
]}

Dixon, Padraig ^{[3
,10
]}

Harrison, Sean ^{[3
,10
]}

Liu, Yi ^{[3
]}

Robinson, Jamie ^{[3
]}

Yarmolinsky, James ^{[3
]}

Haycock, Philip ^{[3
]}

Yuan, Jinqiu ^{[12
,13
,14
,15
]}

Lewis, Sarah ^{[3
]}

Yuan, Zhongshang ^{[16
]}

Gaunt, Tom R. ^{[3
,11
,17
,18
]}

Smith, George Davey ^{[3
,11
,17
,18
]}

Ning, Guang ^{[1
,2
]}

Martin, Richard M. ^{[3
,7
,17
,18
]}

Cui, Bin ^{[1
,2
]}

Wang, Weiqing ^{[1
,2
]}

Bi, Yufang ^{[1
,2
]}

机构：

[1] Shanghai Jiao Tong Univ, Ruijin Hosp, Shanghai Inst Endocrine & Metab Dis, Dept Endocrine & Metab Dis,Sch Med, Shanghai, Peoples R China

[2] Shanghai Jiao Tong Univ, Ruijin Hosp, Shanghai Natl Clin Res Ctr Metab Dis, Natl Hlth Commiss PR China,Shanghai Digital Med In, Shanghai, Peoples R China

[3] Univ Bristol, Bristol Med Sch, MRC Integrat Epidemiol Unit IEU, Oakfield House, Bristol BS8 2BN, England

[4] Shanghai Jiao Tong Univ, Ruijin Hosp, Shanghai Inst Immunol, Ctr Immune Related Dis,Sch Med, Shanghai, Peoples R China

[5] Shanghai Jiao Tong Univ, Shanghai Inst Immunol, Dept Immunol & Microbiol, State Key Lab Oncogenes & Related Genes,Sch Med, Shanghai 200025, Peoples R China

[6] Univ Hong Kong, Li Ka Shing Fac Med, Sch Nursing, Hong Kong, Peoples R China

[7] Univ Hong Kong, Li Ka Shing Fac Med, Sch Publ Hlth, Hong Kong, Peoples R China

[8] Lab Data Discovery Hlth D24H, Hong Kong Sci Pk,Hong Kong Sci & Technol Pk, Hong Kong, Peoples R China

[9] Univ Bristol, Bristol Med Sch, Populat Hlth Sci, Bristol BS8 2PS, England

[10] Univ Oxford, Nuffield Dept Primary Care Hlth Sci, Oxford OX2 6GG, England

[11] Univ Bristol, Bristol Med Sch, Dept Populat Hlth Sci, Bristol BS8 2BN, England

[12] Sun Yat sen Univ, Affiliated Hosp 7, Clin Res Ctr, Shenzhen 518107, Guangdong, Peoples R China

[13] Sun Yat sen Univ, Affiliated Hosp 7, Ctr Digest Dis, Shenzhen 518107, Guangdong, Peoples R China

[14] Guangzhou Women & Children Med Ctr, Guangzhou 510623, Guangdong, Peoples R China

[15] Chinese Univ Hong Kong, JC Sch Publ Hlth & Primary Care, Div Epidemiol, Hong Kong, Peoples R China

[16] Shandong Univ, Cheeloo Coll Med, Sch Publ Hlth, Dept Biostat, Jinan, Peoples R China

[17] Univ Hosp Bristol & Weston NHS Fdn Trust, NIHR Biomed Res Ctr, Bristol, England

[18] Univ Bristol, Bristol, England

来源：

CELL REPORTS MEDICINE | 2024年 / 5卷 / 08期

基金：

中国国家自然科学基金; 英国医学研究理事会; 英国惠康基金;

关键词：

RISK; EPIDEMIOLOGY; ASSOCIATION; INSTRUMENTS; MEDICATION; UPDATE; ADULTS;

D O I：

10.1016/j.xcrm.2024.101688

中图分类号：

Q2 [细胞生物学];

学科分类号：

071009 ; 090102 ;

摘要：

We evaluated the effect of sodium-glucose cotransporter 2 (SGLT2) inhibition on prostate cancer by evidence triangulation. Using Mendelian randomization, we found that genetically proxied SGLT2 inhibition reduced the risk of overall (odds ratio = 0.56, 95% confidence interval [CI] = 0.38 to 0.82; 79,148 prostate cancer cases and 61,106 controls), advanced, and early-onset prostate cancer. Using electronic healthcare data ( n SGLT2i = 24,155; n DPP4i = 24,155), we found that the use of SGLT2 inhibitors was associated with a 23% reduced risk of prostate cancer (hazard ratio = 0.77, 95% CI = 0.61 to 0.99) in men with diabetes. Using data from two prospective cohorts ( n 4C = 57,779; n UK_Biobank = 165,430), we found little evidence to support the association of HbA1c 1c with prostate cancer, implying a non-glycemic effect of SGLT2 inhibition on prostate cancer. In summary, this study provides multiple layers of evidence to support the beneficial effect of SGLT2 inhibition on reducing prostate cancer risk. Future trials are warranted to investigate whether SGLT2 inhibitors can be recommended for prostate cancer prevention.

引用

页数：17

共 50 条

[1] SGLT2 inhibition, circulating proteins, and insomnia: A mendelian randomization study
Luo, Jinlan
Tu, Ling
Zhou, Chenchen
Li, Gen
Shi, Lili
Hu, Shuiqing
SLEEP MEDICINE, 2024, 119 : 480 - 487
[2] Pharmacological targets of SGLT2 inhibition on prostate cancer mediated by circulating metabolites: a drug-target Mendelian randomization study
Lin, Yilong
Zhang, Yue
Wang, Songsong
Cao, Lin
Zhao, Ruidan
Ma, Xilai
Yang, Qiaolu
Zhang, Liyi
Yang, Qingmo
FRONTIERS IN PHARMACOLOGY, 2024, 15
[3] SGLT2 inhibition, circulating metabolites, and atrial fibrillation: a Mendelian randomization study
Jiang Li
Yuefeng Yu
Ying Sun
Bowei Yu
Xiao Tan
Bin Wang
Yingli Lu
Ningjian Wang
Cardiovascular Diabetology, 22
[4] SGLT2 inhibition, circulating metabolites, and atrial fibrillation: a Mendelian randomization study
Li, Jiang
Yu, Yuefeng
Sun, Ying
Yu, Bowei
Tan, Xiao
Wang, Bin
Lu, Yingli
Wang, Ningjian
CARDIOVASCULAR DIABETOLOGY, 2023, 22 (01)
[5] SGLT2 inhibition, blood lipids, and cardiovascular disease: A Mendelian randomization study
Li, Jiangtao
Li, Chenhe
Feng, Xin
Wei, Xiang
ESC HEART FAILURE, 2024, 11 (06): : 3960 - 3971
[6] SGLT2 Inhibition, Choline Metabolites, and Cardiometabolic Diseases: A Mediation Mendelian Randomization Study
Xu, Min
Zheng, Jie
Hou, Tianzhichao
Lin, Hong
Wang, Tiange
Wang, Shuangyuan
Lu, Jieli
Zhao, Zhiyun
Li, Mian
Xu, Yu
Ning, Guang
Bi, Yufang
Wang, Weiqing
DIABETES CARE, 2022, 45 (11) : 2718 - 2728
[7] SGLT2 inhibition, circulating biomarkers, and Alzheimer's disease: A Mendelian randomization study
Yang, Hao
Ning, Yuye
Chen, Meilin
Jia, Jianping
JOURNAL OF ALZHEIMERS DISEASE, 2025, 103 (04) : 1126 - 1134
[8] The Effect of SGLT2 Inhibition on Brain-related Phenotypes and Aging: A Drug Target Mendelian Randomization Study
Chen, Zhihe
Wu, Xueyan
Yang, Qianqian
Zhao, Huiling
Ying, Hui
Liu, Haoyu
Wang, Chaoyue
Zheng, Ruizhi
Lin, Hong
Wang, Shuangyuan
Li, Mian
Wang, Tiange
Zhao, Zhiyun
Xu, Min
Chen, Yuhong
Xu, Yu
Lu, Jieli
Ning, Guang
Wang, Weiqing
Luo, Shan
Au Yeung, Shiu Lun
Bi, Yufang
Zheng, Jie
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2024,
[9] Exploring the effect of SGLT2 inhibitors on the risk of primary open-angle glaucoma using Mendelian randomization analysis
Yujin Guo
Jing Zhao
Shuai Hou
Zhiqing Chen
Scientific Reports, 15 (1)
[10] SGLT2 inhibition, high-density lipoprotein, and kidney function: a mendelian randomization study
Zhijuan Wang
Jie Wei
Wenman Zhao
Rui Shi
Yuyu Zhu
Xunliang Li
Deguang Wang
Lipids in Health and Disease, 23

← 1 2 3 4 5 →